Speakers. Text to be added
|
|
- Katrina Lane
- 6 years ago
- Views:
Transcription
1 Speakers SESSION 1 Clinical status and perspectives for hereditary breast and ovarian cancer (HBOC) risk prediction. Fergus Couch Mayo Clinic Cancer Center and the Center for Individualized Medicine, Diana Eccles University of Southampton, Southampton, UK Professor Eccles is the Head of the Cancer Sciences Academic Unit which incorporates the Southampton Cancer Research UK Centre, the Southampton Clinical Trials Unit and links closely through our clinical academics to Cancer Care at UHS. She continues to work as an NHS consultant in clinical cancer genetics which encompasses diagnosis and management of many different genetic conditions that predispose to tumour development in families. Rita Schmutzler University Hospital Cologne, Germany Fam. Breast and Ovarian Cancer Sabine Linn Cancer Institute, The Linn lab focuses on the development of prognostic and predictive markers for breast and ovarian cancer to guide systemic therapy decisions. SESSION 2 Identification of novel HBOC genes and variants Claus Storgaard Sørensen Biotech Research & Innovation Center, University of Copenhagen, Denmark My team is investigating genome maintenance pathways including their close links with cell proliferation control. We are particularly interested in familial breast and ovarian cancer where we focus on factors and mechanisms that limit tumorigenesis. Bjarni Jóhann Vilhjálmsson Center for Bioinformatics (BiRC), University of Aarhus, Denmark I am fascinated by genetics, and how small genetic differences leads to phenotypic diversity that shapes our lives. Fueled by curiosity, I have spent my research career on developing statistical methods for understanding the genetic architecture of traits and diseases. This includes methods for detecting genetic associations in genome-wide association studies, and more recently, polygenic trait prediction and genetic disease risk assessment. Stefano Annunziato Cancer Institute, Modeling of breast cancer using nongermline mouse model approaches.
2 SESSION 3 Analysis of the effects of HBOC gene variants on treatment response. Lisa Wiesmüller University Hospital Ulm, Germany Our laboratory has developed and/or established powerful assay systems for the quantitative and qualitative analysis of DSB repair, recombination and replication stress response mechanisms in immortalized and primary cells from different organs. Violeta Serra Vall d Hebron Institute of Oncology, Spain Identification of response biomarkers to targeted therapy using PDX models of breast cancer. Oded Kopper Hubrecht Institute, The main focus of my research is establishing new platforms for studying ovarian cancer. We are developing 3D culture systems that will support long-term expansion of ovarian cancer organoids, which would recapitulate both the diversity and heterogeneity of the disease. Fallopian tube (FT) and ovary surface epithelium (OSE) are believed to be the origin of high grade serous ovarian cancer (HGSOC), the most common type of ovarian cancer (~70%). Recently, we have established normal FT and OSE organoid systems. Using crispr-cas9 technology we genetically manipulate these organoids in order to investigate the role of different genes and pathways in the development of HGSOC. SESSION 4 Model systems and assays for the functional classification of HBOC gene variants. Bas Vroling Bio-Prodict, At Bio-Prodict we design and build information systems for protein (super)families, tailored towards fundamental and applied research in Protein Engineering and DNA Diagnostics. These systems contain large amounts of very heterogeneous but highly integegrated data, e.g. alignment-derived data, structure data and information extracted from the literature. I am currently exploring novel ways of applying machine learning technology to predict the effect of nssnps on protein function. Joey Riepsaame Sir William Dunn School of Pathology, University of Oxford, UK. Developing in vivo and in vitro crispr-cas9 approaches. Michel Cannieux Integrated DNA Technologies, The development of tools and solutions to facilitate Genome Editing. This includes development of effectors (Cas9 variants & Cas9 alternatives, and RNA triggers), controls, detection and visualization systems (fluorescence, PCR, NGS). Alvaro NA Monteiro Moffitt Cancer Center, We are interested in the role of germline and somatic genetic factors involved in cancer predisposition, initiation, progression, and response to therapy. Our focus has been on four cancer sites: lung, brain, breast, and ovary. The overarching theme across these cancer sites is the systems biology approaches and genetics to perform in-depth studies with a view to develop translational solutions to cancer therapy and prevention.
3 Peter Bouwman Cancer Institute, The focus of my research is on hereditary breast cancer, with special emphasis on the suppressor gene BRCA1. Together with my co-workers in the group of Jos Jonkers, I have generated several novel mouse models for BRCA1 associated tumorigenesis and used these to get more insight in the function of BRCA1 in tumor suppression and treatment response. Currently, I am focusing on the functional classification of BRCA1 sequence variants of unknown clinical significance. Maaike Vreeswijk Dept.of Human Genetics, University Medical Center, Our research is focused on the DNA damage response and the translation towards clinical applications. We have developed tools for the reliable assessment of the clinical significance of Variants of Uncertain Significance in breast and ovarian cancer susceptibility genes. Haico van Attikum Dept. of Human Genetics, Leiden University, We study how cells repair DNA damage in the context of chromatin and use our expertise to development assays for the functional analysis of sequence variants in cancer. Sean Tavtigian Huntsman Cancer Institute, University of Utah, SESSION 5 Novel insights in HBOC suppression and consequences for functional assays. Shyam Sharan Center for Advanced Preclinical Research, National Cancer Institute, Over the past decade, the overarching goal of our laboratory has been to understand the functional significance of human BRCA1 and BRCA2 variants of unknown clinical significance (VUS). We have used a mouse embryonic stem (ES) cells-based assay developed in our laboratory. Desired variants are generated in the human BRCA1 or BRCA2 gene in bacterial artificial chromosomes (BAC) using recombineering technology. These are then introduced into ES cells engineered to express a conditional-selectable allele of BRCA1 or BRCA2. The extent to which specific variants complement the lethality of ES cells with BRCA1 or BRCA2 deficiency and the known functions of these proteins in DNA repair cell and cycle regulation is used as a surrogate readout to decipher their association with risk of developing the disease.to assess the physiological significance of our findings, we are also engaged in generation of new mouse models. These models serve as power powerful tools that have improved our understanding of the effect of these variants on growth and development, hematopoiesis, fertility and tumorigenesis. Ralph Scully Beth Israel Deaconess Medical Center, Harvard University, Arnab Ray Chaudhuri National Cancer Institute, Using mouse models and a combination of single molecule, cell biological and biochemical approaches, we investigate the mechanisms underlying stability of the DNA replication process and its contribution to genome integrity. We are particularly focused on understanding how mutations in certain factors result in chemo-resistance in Breast and Ovarian cancers by mediating replication fork stability.
4 Organisers Marjanka Schmidt Our work focuses on the effects of genetic variants on risk of breast cancer subtypes, prognosis and long-term outcome of breast cancer. We investigate the interactions between germline variants and life style on the incidence of specific breast cancer subtypes, and the interactions between germline variants, tumor genetic and molecular characteristics, breast cancer treatment, and lifestyle factors on breast cancer prognosis, incidence of second tumors, and mortality. A second research line focuses on patient information and consent procedures, and return of results from research using human materials. This directly relates to the first research line as increasingly studies generate genetic information about hereditary variants. Arne N. Kousholt I work as a postdoc in the lab of Jos Jonkers. My research projects include developing mouse models to functionally investigate BRIP1 as a tumour suppressor for breast cancer, and test treatment strategies for BRIP1 deficient tumours using these mouse models. Moreover, I am working on setting up crispr-cas9 based in-vitro assays to identify pathogenic BRIP1 germline variants. These variants have been identified in high-risk breast cancer families by large scale sequencing efforts. Jos Jonkers The focus of my research is on the genetic dissection of human breast cancer through the use of genetically engineered mouse models (GEMMs) and patient-derived xenograft (PDX) models. My group has generated several mouse models for BRCA1/2-associated hereditary breast cancer and E cadherin-mutated invasive lobular breast cancer. These models are used for both basic and translational studies focusing on genotype-phenotype correlations; discovery and validation of cancer genes and drug targets; tumor-host interactions; and mechanisms of therapy response and resistance. Haico van Attikum We study how cells repair DNA damage in the context of chromatin and use our expertise to development assays for the functional analysis of sequence variants in cancer. Peter Bouwman The focus of my research is on hereditary breast cancer, with special emphasis on the suppressor gene BRCA1. Together with my co-workers in the group of Jos Jonkers, I have generated several novel mouse models for BRCA1 associated tumorigenesis and used these to get more insight in the function of BRCA1 in tumor suppression and treatment response. Currently, I am focusing on the functional classification of BRCA1 sequence variants of unknown clinical significance.
5 Sabine Linn The Linn lab focuses on the development of prognostic and predictive markers for breast and ovarian cancer to guide systemic therapy decisions. Maaike Vreeswijk Our research is focused on the DNA damage response and the translation towards clinical applications. We have developed tools for the reliable assessment of the clinical significance of Variants of Uncertain Significance in breast and ovarian cancer susceptibility genes.
Germline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationConflicts of Interest
This is great information, but how do I use it?: Information needs of genetic counselors related to reclassification of Variants of Uncertain Significance Courtney Scherr, PhD Moffitt Cancer Center Teri
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationPreventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities
BANBURY CENTER REPORTS Preventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor,
More informationPersonalised Medicine in Practice. Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil
Personalised Medicine in Practice Dr Ingrid Slade MBChB, PhD, MRCPCH, MFPH Dr Chris Spencer DPhil Dr Gabriele De Luca MD, DPhil Personalised Medicine in Cancer Care Personalised Medicine in Cancer Care
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationDissection of breast cancer development and therapy resistance in mouse models. Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
Dissection of breast cancer development and therapy resistance in mouse models Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands GEMMs of human cancer Genetically engineered mouse models
More informationFunctional validation of cancer susceptibility genes using gene editing
Functional validation of cancer susceptibility genes using gene editing 2-22-2017 Sabine Topka Research Fellow Niehaus Center for Inherited Cancer Genomics www.mskcc.org Inherited Predisposition to Cancer
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationHuman Genetics 542 Winter 2018 Syllabus
Human Genetics 542 Winter 2018 Syllabus Monday, Wednesday, and Friday 9 10 a.m. 5915 Buhl Course Director: Tony Antonellis Jan 3 rd Wed Mapping disease genes I: inheritance patterns and linkage analysis
More informationCancer Treatment and Research
Cancer Treatment and Research Volume 155 Series Editor Steven T. Rosen For further volumes: http://www.springer.com/series/5808 Boris Pasche Editor Cancer Genetics 123 Editor Boris Pasche, MD, PhD, FACP
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationThe 100,000 Genomes Project
The 100,000 Genomes Project Dr Matina Prapa, Scientific co ordinator Genomics England Clinical Interpretation Partnership William Harvey Research Institute Queen Mary University of London Genomics England
More informationHuman Genetics 542 Winter 2017 Syllabus
Human Genetics 542 Winter 2017 Syllabus Monday, Wednesday, and Friday 9 10 a.m. 5915 Buhl Course Director: Tony Antonellis Module I: Mapping and characterizing simple genetic diseases Jan 4 th Wed Mapping
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationPDX MODELS IN CLINICAL ONCOLOGY AND CANCER PRECISION MEDICINE 3-5 OCTOBER Seminar-Hotel Rigi am See Weggis Switzerland
PDX MODELS IN CLINICAL ONCOLOGY AND CANCER PRECISION MEDICINE 3-5 OCTOBER 2016 Seminar-Hotel Rigi am See Weggis Switzerland Scientific Programme Each speaker in the programme will be careful to allow enough
More informationEx vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent
Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationNotes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina
Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to finally be able to put these genomics related data items
More informationGENETIC SUSCEPTIBILITY TO CANCER
page 1 / 5 page 2 / 5 genetic susceptibility to cancer pdf Coverage Policy...1 General Criteria for Germline Mutation Genetic Testing: Hereditary Cancer Susceptibility/Risk Assessment...2 Genetic Testing
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationGENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2
GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationIntroduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationLearning Outcomes: The following list provides the learning objectives that will be covered in the lectures, and tutorials of each week:
Course Code Course Title ECTS Credits MED-306 Medical Genetics 6 School Semester Prerequisites Medical School Spring (Semester 6) MED-103 Biology I MED-109 Biology II MED-204 Biochemistry I MED-209 Biochemistry
More informationTeacher Resource for: BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity.
Teacher Resource for: BRCA1 Tumor Suppression Depends on BRCT Phosphoprotein Binding, But Not Its E3 Ligase Activity. Table of Contents: I. GENERAL USE OF Science in the Classroom a. Student Learning Goals
More informationBiology Response Controversies and Advances
Biology Response Controversies and Advances in BRCA related ovarian cancer Lessons learned and future directions Michael Friedlander The Prince of Wales Hospital and Royal Hospital for Women Sydney BREAST-CANCER
More informationAsingle inherited mutant gene may be enough to
396 Cancer Inheritance STEVEN A. FRANK Asingle inherited mutant gene may be enough to cause a very high cancer risk. Single-mutation cases have provided much insight into the genetic basis of carcinogenesis,
More informationGenetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine
Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationThe Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno
The Role of Genetics in Ovarian Cancer Screening Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno How Much Breast and Ovarian Cancer Is Hereditary? 15%-20% 5%-10% Breast Cancer
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationIntroduction to Cancer Bioinformatics and cancer biology. Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015
Introduction to Cancer Bioinformatics and cancer biology Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015 Why cancer bioinformatics? Devastating disease, no cure on the horizon Major
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More informationPancreas Cancer Genomics
Pancreas Cancer Genomics Steven Gallinger MD, MSc, FRCS HPB Surgical Oncology Program University Health Network Samuel Lunenfeld Research Institute Mount Sinai Hospital University of Toronto Fate of the
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationPHD STUDENTSHIP PROJECT PROPOSAL
The Institute of Cancer Research PHD STUDENTSHIP PROJECT PROPOSAL PROJECT DETAILS Project Title: Short Project Title: SUPERVISORY TEAM Primary Supervisor(s): Understanding therapeutic responses in BRCA
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationCOST ACTION CA IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN)
COST ACTION CA17118 - IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN) Working group 1 management committee duties - Contribute
More informationACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome
Hereditary Ovarian and Breast Cancer Syndrome C. Blake Gilks, MD Dept of Pathology Vancouver General Hospital University of British Columbia Blake.gilks@vch.ca The USCAP requires that anyone in a position
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationGenetic Screening Visit
Before your visit In a typical hereditary breast ovarian cancer genetic counsling visit be prepared to answer the following set of questions, please check were applicable. About your self (same questions
More informationComputational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 11-16-2017 Computational Investigation of Homologous Recombination DNA Repair
More informationA Strategic Centre for Translational Cancer Research Lund University
A Strategic Centre for Translational Cancer Research Lund University Our recent achievements During the recent five years CREATE Health has focused on biomarkers mainly for cancer diagnosis and prognosis.
More informationBRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI
BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI DR KIRTI CHADHA MD (Path), PDCC (Oncopath & Oncohemat) CONSULTANT SURGICAL PATHOLOGIST NATIONAL COORDINATOR,SURGICAL PATHOLOGY
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2012: Schmutzler with Albert / Blohmer /
More informationAccelerating Translation at Dana-Farber Cancer Institute*
Accelerating Translation at Dana-Farber Cancer Institute* *and our partner institutions February 12, 2013 Edward J Benz JR, MD Dana Farber Cancer Institute 1 2 Academic Structure All Dana-Farber faculty
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationEuropean School of Genetic Medicine 8th COURSE IN CANCER GENETICS September 5-9, 2003 Bertinoro, Forlì, Italy
European School of Genetic Medicine 8th COURSE IN CANCER GENETICS September 5-9, 2003 Bertinoro, Forlì, Italy University Residential Centre via Frangipane, 6 - Bertinoro, Forlì Tel. +39 0543 446500, Fax
More informationCOST ACTION CA IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN)
COST ACTION CA17118 - IDENTIFYING BIOMARKERS THROUGH TRANSLATIONAL RESEARCH FOR PREVENTION AND STRATIFICATION OF COLORECTAL CANCER (TRANSCOLOCAN) Working group 1 participant duties - Align with the scientific
More informationOverdiagnosis in Genetic Screening: Uncertainty
National Cancer Institute Overdiagnosis in Screening: Uncertainty Barbara Dunn, NCI/Division of Cancer Prevention Kathy Helzlsouer, NCI/Division of Cancer Control and Population Sciences U.S. DEPARTMENT
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationCertificate of Advanced Studies in Personalized Molecular Oncology
Certificate of Advanced Studies in Personalized Molecular Oncology Certificate of Advanced Studies (CAS) in Personalized Molecular Oncology Overview Cutting-edge technologies, like next-generation-sequencing
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationTOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad
TOUR REPORT Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad 1. Name and Designation of ICMR IF : Dr. A. Venkateshwari, Assistant Professor 2. Address: Dr.
More informationSHARSHERET. New Recommendations for Genetic Testing: How Do I Make Sense Of It All?
Sharsheret 2018 SHARSHERET New Recommendations for Genetic Testing: How Do I Make Sense Of It All? Wednesday, December 19, 2018 To listen to the presentation by phone: Dial: 1 (415) 655-0052 Access Code:
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationHereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors. Vanessa Miraj Stuyvesant High School May 20,2013
+ Hereditary Breast and Ovarian Cancer: BRCA1 Failure and the Effectiveness of PARP Inhibitors Vanessa Miraj Stuyvesant High School May 20,2013 + Physiology q 3-10% of breast or ovarian cancers are considered
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationQuantitative Radiomics System Decoding the Tumor Phenotype. John Quackenbush and Hugo Aerts
Quantitative Radiomics System Decoding the Tumor Phenotype John Quackenbush and Hugo Aerts The Radiomics Hypothesis The tumor s structural phenotype reflects its molecular and clinical properties. This
More informationStudying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy
Kavya Puchhalapalli CALS Honors Project Report Spring 2017 Studying The Role Of DNA Mismatch Repair In Brain Cancer Malignancy Abstract Malignant brain tumors including medulloblastomas and primitive neuroectodermal
More informationThe Deciphering Development Disorders (DDD) project: What a genomic approach can achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationCELL CYCLE REGULATION AND CANCER. Cellular Reproduction II
CELL CYCLE REGULATION AND CANCER Cellular Reproduction II THE CELL CYCLE Interphase G1- gap phase 1- cell grows and develops S- DNA synthesis phase- cell replicates each chromosome G2- gap phase 2- cell
More informationCHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology. Non-clinical models: Tumour Models - Proof of Concept
CHMP Oncology Working Party Workshop on: Histology Independent Indications in Oncology Non-clinical models: Tumour Models - Proof of Concept Edward C. Rosfjord Pfizer Worldwide R. & D. 14 December 2017
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Version 2003: Kiechle / Schmutzler Versions 2004 2011:
More informationBiology of Ovarian Cancer
Biology of Ovarian Cancer John W. Moroney, M.D. Associate Professor Department of Obstetrics and Gynecology Department of Medicine University of Chicago Pritzker School of Medicine Disclosure No conflicts
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationClinical Utility of Actionable Genome Information in Precision Oncology Clinic
Indian Ocean Rim 2017 Laboratory Haematology Congress 2017. 6.18-19, Singapore Clinical Utility of Actionable Genome Information in Precision Oncology Clinic Reimbursement program for NGS panel tests in
More informationWhat All of Us Should Know About Cancer and Genetics
What All of Us Should Know About Cancer and Genetics Beth A. Pletcher, MD, FAAP, FACMG Associate Professor of Pediatrics UMDNJ- New Jersey Medical School Disclosures I have no relevant financial relationships
More informationSINGAPORE SCIENTISTS DISCOVER NEW PATHWAYS LEADING TO CANCER PROGRESSION
MEDIA RELEASE FOR IMMEDIATE RELEASE 18 JULY 2016 SINGAPORE SCIENTISTS DISCOVER NEW PATHWAYS LEADING TO CANCER PROGRESSION SINGAPORE Scientists from A*STAR s Genome Institute of Singapore (GIS) and the
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-05-1-0494 TITLE: Tumor Suppression by BRCA-1: A Critical Role at DNA Replication Forks PRINCIPAL INVESTIGATOR: Jean Gautier, Ph.D. CONTRACTING ORGANIZATION: Columbia University
More informationGENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center
GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center Definitions: DNA: The material found in our cells - the instructions
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More information